Skip to content
Combined Shape Created with Sketch.
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • Subscribe
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

European Medicines Agency

01.13.21

EMA Receives Conditional Marketing Request for AstraZeneca’s COVID-19 Vaccine

Source: FirstWord

01.07.21

Moderna’s COVID-19 Vaccine Becomes Second to Nab EU Authorization

Source: FirstWord

11.03.20

GenSight Biologics Reports Validation of Lumevoq Marketing Authorization Application (MAA) by European Medicines Agency

Source: GenSight Biologics

10.06.20

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of Proposed Lucentis Biosimilar

Source: Samsung Bioepis

10.02.20

EMA Starts Rolling Review of AstraZeneca’s COVID-19 Vaccine Candidate AZD1222

Source: FirstWord

06.29.20

Novartis Withdraws Marketing Application of Dry Eye Drug Xiidra in Europe

Source: Eyewire News

04.06.20

EU Body Backs Compassionate Use of Gilead’s Remdesivir for COVID-19

Source: FirstWord

03.02.20

EMA Grants Two Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosa

Source: Janssen

01.02.20

Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda Marketing Authorization Application in Europe

Source: Aerie Pharmaceuticals

12.16.19

Novartis Receives Positive CHMP Opinion for Beovu (Brolucizumab) for the Treatment of Wet AMD

Source: Novartis

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Cornea
  • Glaucoma
  • Healthcare
  • Innovation
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2021 Bryn Mawr Communications, LLC.

All Rights Reserved.